What is the proper dose of Artemether (artemether) for treating uncomplicated malaria?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Artemether Dosing for Malaria Treatment

For uncomplicated P. falciparum malaria, artemether-lumefantrine (AL) should be dosed as 4 tablets (20/120 mg) at 0 hours, 4 tablets at 8 hours on day 1, then 4 tablets twice daily on days 2 and 3 (total of 24 tablets over 72 hours) for adults >35 kg, and must be taken with a fatty meal or drink to ensure adequate absorption. 1, 2, 3

Standard Dosing Regimen for Uncomplicated Malaria

The artemether-lumefantrine dosing schedule is weight-based: 1

  • 5-<15 kg: 1 tablet per dose
  • 15-<25 kg: 2 tablets per dose
  • 25-<35 kg: 3 tablets per dose
  • ≥35 kg (adults): 4 tablets per dose

Timing: Doses given at 0,8,24,36,48, and 60 hours (6 doses total over 3 days). 1

Critical Administration Requirements

Fat intake is mandatory for adequate lumefantrine absorption. Failure to take AL with a fatty meal or drink results in subtherapeutic drug levels and treatment failure. 1, 2, 3 The medication should be administered with at least 200 mL of milk or a fatty meal to optimize bioavailability. 4

Day 7 lumefantrine concentrations ≥200 ng/mL are associated with >98% cure rates in most patients with parasitemia <135,000/μL. 5 Unsupervised treatment results in 44% lower day 7 concentrations, emphasizing the importance of directly observed therapy when possible. 5

High-Risk Populations Requiring Close Monitoring

Three groups face increased treatment failure risk and warrant enhanced monitoring: 5

  • Very young children (<3 years): Particularly underweight-for-age children who have 23% lower day 7 concentrations than adequately nourished children and 53% lower concentrations than adults. 5
  • Patients with high parasitemia (>135,000/μL): Baseline parasitemia increases recrudescence risk (HR 1.87 per 10-fold increase). 5
  • Patients in areas with emerging artemisinin resistance or very low transmission intensity. 5

Pregnancy Considerations

Artemether-lumefantrine can be used in all trimesters of pregnancy as recommended by WHO and CDC, with cure rates of 99.3% demonstrated in second and third trimester studies. 1, 2, 3 The standard adult dosing regimen applies, with no dose adjustment needed. 1

Severe Malaria

For severe malaria, intravenous artesunate is first-line treatment at 2.4 mg/kg IV at 0,12, and 24 hours, then daily until parasitemia <1%. 2, 3 Once the patient can tolerate oral medication and parasitemia is <1%, complete treatment with a full course of oral artemether-lumefantrine. 2, 3

Important Safety Considerations

QTc prolongation risk: Both artemether and lumefantrine can prolong the QTc interval. Avoid in patients at risk of QTc prolongation or taking medications that prolong QTc. 1, 2, 3

Post-artemisinin delayed hemolysis (PADH): Monitor hemoglobin on days 7,14,21, and 28 after treatment, as PADH occurs in 37.4% of patients using strict definitions. 2, 6

Alternative Dosing Considerations

Swiss guidelines recommend extending treatment to 5 days in patients with high body weight or suspected malabsorption. 2 However, once-daily dosing is not recommended, as it results in 30% lower lumefantrine exposure and reduced efficacy. 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Malaria Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Malaria Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Uncomplicated Malaria in Tanzania

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.